Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic and Split Dosing Selinexor in STS
NCT04811196Phase 1Completed
- Sponsor
- University Health Network
- Start
- Mar 2021
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of selinexor in soft tissue sarcoma (STS), sponsored by University Health Network. Primary endpoints: Incidence of toxicity and safety and Recommended Phase 2 Dose up to 28 days. Started Mar 2021; status: completed.
02
Drugs
selinexor
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04811196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04811196.